SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias sharp selloff is being tied by traders to fears that a Democratic sweep could bring tighter AI regulation or delay data-center projects, alongside broader doubts about AI spending and the sustainability of the chip rally. The community is divided between calling it an AI-bubble unwind and buying the dip on confidence in Nvidias long-term business.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff is being tied by traders to fears that the Democrats midterm gains could bring tighter AI rules and slow data-center investment, adding pressure to tech-heavy indexes. The community is split between seeing the drop as an overreaction and buying opportunity and expecting further losses amid uncertainty and an unwind in AI-related stocks.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp tech-led selloff is being tied by traders to fears that the Democratic midterm sweep could bring tighter AI and data-center rules and slow infrastructure spending, with semiconductor weakness adding pressure. The community is split between seeing a deeper correction and AI-trade unwind ahead and viewing the drop as an overreaction or dip-buying opportunity.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns sharp selloff is being tied by traders to fears that Democratic gains and calls for tighter AI regulation could slow data-center construction and weaken demand for AI-related chips and memory, amid a broader semiconductor and AI-trade unwind. The community is divided between viewing the drop as an overreaction and dip-buying opportunity because AI memory demand remains strong, and warning that weaker AI spending or a prolonged sector reset could bring further declines.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances quarterly results drew attention with record revenue growth, improved gross margins, and a longer cash runway, but the stock sold off despite the strong report. Traders debate whether broad biotech-market weakness and profit-taking drove the decline or whether concerns about Amtagvis sequential growth and the lung-cancer programs durability and 2027 filing timeline are weighing on sentiment.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A sharp semiconductor and AI-stock selloff has drawn attention to AMD, with traders speculating that post-midterm calls for AI regulation could slow data-center construction, alongside broader concerns about AI spending. The drop contrasts with AMDs strong results and outlook; some traders call it an overreaction and buying opportunity, while others see lingering capex and valuation risks.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical-infrastructure stocks, with traders citing concerns about hyperscaler spending, AI valuations and the companys upcoming earnings outlook. Some see the decline as an oversold buying opportunity, while others fear more downside and question whether strong results would be enough to reverse the weak sentiment.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys quarterly results and outlookfeaturing its first GAAP profit since going public, accelerating Vector advertising growth, and upbeat forward guidanceare driving the rally. Traders are largely celebrating a potential turnaround, while some question whether shares can sustain gains and break through resistance.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff has hammered SOXL, with traders pointing to fears that political shifts could constrain AI and data-center investment, alongside broader worries that the AI trade is unwinding. The funds 3x daily leverage has magnified the drop; traders disagree on whether it marks capitulation and a buying opportunity or further downside ahead.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure as semiconductor traders reassess the AI buildout, weighing concerns that data-center restrictions and doubts about returns on heavy AI spending could slow chip demand. The community is split between fears that the AI trade is unraveling and calls that the selloff is an overreaction, with compute demand still intact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday

U.S. stocks mixed; First Tracks Biotherapeutics surged 18% on positive celiac trial results, while C3.ai, Liquidia and others also gained.read more...

Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide

Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide

 US futures are flat, with S&P contracts clinging to small gains and the Nasdaq slipping into the red as memory stocks slide, after a weekend of contradictory geopolitical headlines whipsawed oil...

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

Equity

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results

TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.read more...

TRAX Stock Hits All-Time High — What's Driving The Super Rally?

According to TheFly, HC Wainwright raised its price target on First Tracks to $44 from $30 while maintaining a ‘Buy’ rating.


This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday

Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, including upgrades, downgrades, and initiations.read more...

First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.

First Tracks Biotherapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>TRAX plans to release top-line data from the first ANB033 celiac-disease study cohort on Monday.</li><li>CYTK will present additional Aficamten analyses at HFSA, while EPRX presents previously disclosed EP-104GI data at ACG.</li><li>ARWR and VSTM have clinical updates scheduled for Wednesday on Alzheimer’s research and the cancer drug VS-7375.</li></ul><p>Biotech investors face a packed week, with First Tracks set to report early data on a celiac-disease drug, Verastem preparing an update on a cancer treatment, and the FDA approaching decisions on two eye therapies.</p><p>The&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> gained 2.8% last week, outperforming&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a>, up 1.2%, and&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a>, up 0.2%. The&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> rose 0.6%, trailing SPY but beating QQQ, while the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> fell 0.4%.</p><p><img src="https://news.stocktwits-cdn.com/healthcare_d7c3a475bc.png" alt="healthcare.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>Development</td></tr><tr><td>Oct.12</td><td>TRAX</td><td>First Tracks plans to report Cohort 1 top-line data for ANB033 in celiac disease; investor call at 8:30 a.m. ET</td></tr><tr><td>Oct.12</td><td>CYTK / HFSA</td><td>Two late-breaking analyses of Aficamten in nonobstructive hypertrophic cardiomyopathy at the HFSA meeting</td></tr><tr><td>Oct.12</td><td>EPRX / ACG</td><td>Poster on EP-104GI and dysphagia improvements through 52 weeks in the RESOLVE study</td></tr><tr><td>Oct.13</td><td>JNJ</td><td>Third-quarter results; investor call at 8:30 a.m. ET</td></tr><tr><td>Oct.14</td><td>ARWR</td><td>Webinar with interim clinical data from the ARO-MAPT study in Alzheimer’s disease and other tauopathies</td></tr><tr><td>Oct.14</td><td>VSTM</td><td>Investor event with initial efficacy and updated safety data for VS-7375</td></tr><tr><td>Oct.14-Oct.17</td><td>PHAR / ESID</td><td>Late-breaking presentation of Phase 2 Leniolisib data in primary immunodeficiencies with immune dysregulation</td></tr><tr><td>Oct.15</td><td>RHHBY</td><td>FDA target action date for Roche’s Enspryng in thyroid eye disease</td></tr><tr><td>Oct.17</td><td>VTRS / IRD</td><td>FDA target action date for phentolamine ophthalmic solution 0.75% in presbyopia</td></tr><tr><td>Oct.17-Oct.20</td><td>UEG Week</td><td>Gastroenterology conference in Barcelona, with presentations from EPRX, ABVX, Agomab and PALI</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Monday: TRAX, CYTK and EPRX</strong></h2><p>First Tracks Biotherapeutics plans to report top-line data on Monday from Cohort 1 of its Phase 1b study of ANB033, a drug that blocks the immune target CD122. The gluten-challenge study is testing whether the drug can protect the intestinal lining from damage in people with celiac disease.&nbsp;</p><p>Cytokinetics (CYTK) will present two late-breaking analyses of Aficamten on Monday at the Heart Failure Society of America’s meeting in Phoenix. The ACACIA-HCM analyses examine the drug’s overall effectiveness and impact on exercise performance in nonobstructive hypertrophic cardiomyopathy, where a thickened heart muscle does not block blood flow. The company plans to submit a supplemental new drug application in the fourth quarter.&nbsp;</p><p>Eupraxia Pharmaceuticals (EPRX) will present a poster on Monday at the American College of Gastroenterology meeting on EP-104GI in eosinophilic esophagitis, an inflammatory condition of the esophagus. It will examine improvements in difficulty swallowing that lasted up to 52 weeks in the Phase 1b/2 Resolve study. Eupraxia reported the 52-week results from its highest-dose group late last month.&nbsp;</p><h2 class="st-heading-2"><strong>Midweek: JNJ, ARWR And VSTM</strong></h2><p>Johnson &amp; Johnson (JNJ) will report its third-quarter results on Tuesday. According to Koyfin, analysts expect revenue of $25.38 billion, up 0.3%. They forecast earnings before interest, taxes, depreciation and amortization (EBITDA) at $8.24 billion, down 8%, and earnings before interest and taxes (EBIT) at $7.42 billion, down 10%. GAAP earnings per share (EPS) are projected at $2.07, down 9%.</p><p>On Wednesday, Arrowhead Pharmaceuticals (ARWR) will share interim results from an early-stage study of ARO-MAPT, its treatment for Alzheimer’s disease and other disorders linked to abnormal tau protein. A webinar on the same day will also include an update on the company’s central nervous system pipeline.</p><p>Verastem Oncology (VSTM) will host an investor event on Wednesday to present initial efficacy results and updated safety data for VS-7375. The oral drug targets KRAS G12D, a cancer-driving mutation, and is being studied in pancreatic, lung and colorectal cancers as part of the Target-D program.</p><h2 class="st-heading-2"><strong>FDA Target Dates Loom For 2 Eye Treatments</strong></h2><p>Roche (RHHBY) is awaiting an FDA decision by Thursday on its application to use Enspryng (Satralizumab) to treat thyroid eye disease. The application received Priority Review. If approved, Roche says Enspryng could become the first at-home, under-the-skin treatment for the condition. The Phase 3 SatraGO results were presented last year.</p><p>Viatris (VTRS) and Opus Genetics (IRD) face an Oct.17 FDA target date for phentolamine eye drops, also known as MR-141, as a treatment for presbyopia — the age-related difficulty focusing on nearby objects. The FDA accepted the application seeking approval for this new use.</p><h2 class="st-heading-2"><strong>GI Conferences Bring More Data Presentations</strong></h2><p>Pharming (PHAR) will present previously announced Phase 2 results for Leniolisib at the European Society for Immunodeficiencies meeting, running Oct.14-Oct.17 in the Netherlands. The study involved patients with rare, genetically defined immune disorders. Pharming released the top-line findings last month.&nbsp;</p><p>Meanwhile, the United European Gastroenterology Week runs from Oct.17-Oct.20 in Barcelona. Abivax (ABVX) will present seven Obefazimod abstracts, including results from a Phase 3 maintenance study and patient subgroup analyses, longer-term Phase 2 findings and a preclinical study.</p><p>Agomab will present long-term data from an extension of its STENOVA Phase 2a study, in which patients continued Ontunisertib treatment for up to 60 weeks. The study focuses on fibrostenosing Crohn’s disease, which can cause narrowing of the bowel. Palisade Bio (PALI) will make four presentations on PALI-2108, including Phase 1b findings on early clinical improvements and evidence that the drug affects PDE4, a protein involved in inflammation. Three additional posters will cover gut-targeted delivery, safety and potential biomarkers that could help predict treatment response.</p><p>Separately, Filana Therapeutics (FLNA) said it will attend the Maxim Growth Summit, running Oct.12-Oct.14, for one-on-one meetings.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-retail-big-pharma-buyout-booth-ash/cZx4tMpRBF7">SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&amp;A Negotiation Lounge' Booth At ASH&nbsp;</a></p>

Current Price	$45.62
Prev Close	$49.04
Open	$48.04
Dividend Yield	N/A
50-Day Moving Average	$39.10
Beta	2.64
Avg. Volume	1.15M
PE Ratio	N/A

52-Week High	$50.17
52-Week Low	$14.72
Market Capitalization	$2.06B
EPS (Annual)	-$4.76
Price to Book	11.66
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

TRAX Fundamentals